PB
Puma Biotechnology, Inc.
PBYI · NASDAQ
$9.60 +0.95% (+$0.09)
1M +5.38%
Market Cap $484.6M
P/E Ratio 18.14x
Div. Yield -
ROE 20.85%
Bulios Fair Price
$6.65
30.7% downside
Current Price
$9.6
Undervalued Fair Value Overvalued
According to Bulios Fair Price, PBYI is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Strong
7/9Valuation
71 /100
Cheap EV/EBITDA 9.50x
P/S 2.10x
P/B 3.50x
Growth
63 /100
Stable Rev. growth 0.05%
Book val. growth 82.03%
EPS growth 210.89%
Profitability
81 /100
Strong Net margin 11.55%
Op. margin 13.16%
FCF margin 17.80%
Quality
95 /100
Excellent ROE 20.85%
ROA 13.86%
Asset turnover 1.20x
Debt
97 /100
Low Current ratio 2.91x
Int. coverage 9.86x
Net debt/EBITDA -0.67x
Stability
55 /100
Moderate Rev. volatility 2.89%
EPS volatility 1,211.83%
Profitable years 4
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about PBYI
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Alan H. Auerbach
Employees
179
Headquarters
Los Angeles
Upcoming events
05 NOV
Earnings
Upcoming earnings report